For all media enquiries, please contact Breakthrough Media Centre:
Press office
Email: press@breakthrough.org.uk
Tel: 020 7025 2432 / 2460
Fax: 020 7025 2401
Out of hours: 07778 682001
News and Events
-
Paradox of cancer drugs gives clues as to why some treatments fail
22 Mar 2009Research from scientists now at the Breakthrough Research Centre has found that some types of cancer drugs called angiogenesis inhibitors can encourage tumour growth rather than stunt it - according to research published in Nature Medicine.
-
Domainex Collaboration on Novel Drug Targets
20 Mar 2009Domainex today announced a collaboration on new exciting drug discovery programmes with the Breakthrough Breast Cancer Research Centre and The Institute of Cancer Research (ICR) to identify and develop inhibitors of two recently validated breast cancer targets, tankyrase and IKK-epsilon.
-
The Institute of Cancer Research Centenary Conference
25 Feb 2009The Institute of Cancer Research Centenary Conference Cancer Genes: Discovery and Exploitation 8th-10th June 2009
-
Breakthrough Breast Cancer opens £4.2m London research unit to find treatments for aggressive type of breast cancer
12 Feb 2009Breakthrough Breast Cancer opens a new £4.2m research unit dedicated to finding treatments for and ways of preventing an aggressive type of breast cancer today.
-
Research by Breakthrough Breast Cancer-funded scientists in West London has been recognised as world class.
18 Dec 2008Work taking place at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London has helped The Institute become the top ranked UK Higher Education Institution for research quality, according to a table of excellence prepared by the Times Higher Education.
-
Genomic Health Announces Study Establishing the Utility of Oncotype DX® in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
15 Dec 2008Genomic Health, Inc. has announced findings from a European study, involving Professor Mitch Dowsett, Royal Marsden Hospital and Team Leader at the Breakthrough Breast Cancer Research Centre in London, which demonstrated that the Oncotype DX Recurrence Score® result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive breast cancer patients who are treated with the aromatase inhibitor anastrozole or with tamoxifen.
-
Antisoma collaboration on novel approach to cancer treatment
07 Oct 2008Cancer drug developer Antisoma (LSE: ASM; USOTC: ATSMY), The Institute of Cancer Research (The Institute) and Cancer Research Technology (CRT) today announced a collaboration and licensing agreement under which Antisoma has acquired rights to develop and commercialise novel anti-cancer compounds called PPM1D (protein phosphatase magnesium-dependent 1 ) inhibitors. Work carried out at the Breakthrough Breast Cancer Research Centre and at the Cancer Research UK Centre for Cancer Therapeutics, both of which are at The Institute, showed that these compounds inhibit PPM1D and selectively kill cells that over-express this phosphatase.
-
Breakthrough Breast Cancer funds doctor to forward cutting-edge breast cancer research
02 Oct 2008A new research fellowship programme by the UK’s leading breast cancer charity, Breakthrough Breast Cancer, has awarded its first grant of over £900,000 to allow an oncologist to establish a laboratory to undertake vital research into HER2 positive breast cancer.
-
New Team Joins the Breakthrough Research Unit, Manchester
01 Oct 2008Professor Göran Landberg, joins us as the first team leader of the new Breakthrough Research Unit, at the University of Manchester.
-
How does knowledge of genetic and life-style factors help us prevent breast cancer?
30 Sep 2008Following a successful event in 2007, Breakthrough Breast Cancer and Breast Cancer Campaign will be hosting another joint evening event at the NCRI conference at 8pm on Sunday 5th October.
-
HRH The Prince of Wales officially opens the Edinburgh Research Unit
05 Jun 2008Breakthrough Breast Cancer’s groundbreaking new research unit in Edinburgh is officially opened today by HRH The Prince of Wales (also known as The Duke of Rothesay while travelling in Scotland), the charity’s Patron.
-
Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Centre, becomes a Fellow of the Royal Society
16 May 2008Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London, has today been elected as a Fellow of the Royal Society.
-
CDK10 is an Important Determinant of Resistance to EndocrineTherapy
05 Feb 2008Scientists at the Breakthrough Breast Cancer Research Centre have identified how some breast cancers may become resistant to hormone treatments like tamoxifen. The study, published in the February issue of Cancer Cell, shows for the first time that a protein called CDK10 is able to control the development of tamoxifen resistance in hormone sensitive breast cancer, and has potentially important implications in the treatment of women with this form of the disease.
-
Debate at NCRI conference
25 Sep 2007Breakthrough Breast Cancer and Breast Cancer Campaign will be holding a joint debate at the NCRI conference in Birmingham on Sunday 30th September. The debate is titled 'Breast cancer prevention in 2025: targeted chemoprevention or lifestyle change'.
-
Patients begin enrolling in studies to determine if women with BRCA 1 & 2 positive cancer may receive greater benefit from new treatment
19 Jun 2007AstraZeneca Collaborates with Myriad Genetics on Phase 2 Trials. AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 positive breast and ovarian cancer. Myriad Genetics, Inc. (Nasdaq: MYGN, www.myriad.com), is providing the molecular diagnostic testing (BRACAnalysis™) for these trials. Dr Andrew Tutt, clinician scientist at the Breakthrough Breast Cancer Research Centre and breast oncologist at Guy’s Hospital, London is Lead Investigator for the trials.
-
BRCA1 dysfunction in sporadic basal-like breast cancer
29 Mar 2007Breakthrough scientists have identified a high prevalence of BRCA1 dysfunction in basal-like breast cancers. This finding could be exploited to develop novel targeted therapies for this particular type of breast cancer.
-
FGFR1 as a potential therapeutic target for lobular breast carcinomas
11 Dec 2006Breakthrough scientists have identified FGFR1 as a potential therapeutic target, for lobular breast carcinomas. The findings now published in the Journal of Clinical Cancer Research.
-
Are biomarker changes preferable to clinical response as markers of treatment benefit? An evening debate.
28 Sep 2006Professor Mitch Dowsett will be speaking at this years joint debate, hosted by Breakthrough Breast Cancer and Breast Cancer Campaign, at the NCRI conference.
